The prognostic significance and Immunomodulatory role of SCGB3A1 expression in stage I lung adenocarcinoma.

IF 2 4区 医学 Q3 GENETICS & HEREDITY
Xin Zhang, ShiNing Li, Yujin Lv, XinYu Liu, Yong Ao, LeQi Zhong, Yi Hu
{"title":"The prognostic significance and Immunomodulatory role of SCGB3A1 expression in stage I lung adenocarcinoma.","authors":"Xin Zhang, ShiNing Li, Yujin Lv, XinYu Liu, Yong Ao, LeQi Zhong, Yi Hu","doi":"10.1186/s12920-025-02192-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Many early-stage lung adenocarcinoma patients experience recurrence or metastasis after surgery, and the efficacy of targeted therapies remains suboptimal, significantly impacting the prognosis of these patients. Our study aims to investigate the impact of SCGB3A1 on the prognosis of lung adenocarcinoma patients and its role in immunity. We propose that SCGB3A1 may offer a novel treatment approach for lung adenocarcinoma patients who do not respond well to targeted therapies.</p><p><strong>Methods: </strong>We obtained RNA sequencing data from 539 lung adenocarcinoma samples, 59 normal tissues, and 2 metastatic cancer tissues from The Cancer Genome Atlas database. Using Venn diagrams, we analyzed the expression of SCGB3A1 and other differentially expressed genes (DEGs) in different patient groups. Additionally, we performed another Venn diagram analysis to explore the association between SCGB3A1 and immune-related genes. We investigated the relationship between SCGB3A1 expression and patient clinical-pathological data and prognosis. Furthermore, through GO, KEGG, and GSEA enrichment analyses, we explored the functional roles of SCGB3A1 and its association with immune cell infiltration and immune checkpoint genes. The role of SCGB3A1 in LUAD was investigated by cytological experiments.</p><p><strong>Results: </strong>The results indicated that SCGB3A1 is associated with both prognosis and immunity. In lung adenocarcinoma, SCGB3A1 may function as a tumor suppressor gene. The high-expression group of SCGB3A1 exhibited a better prognosis and more pronounced immune cell infiltration. Additionally, SCGB3A1 was associated with smoking status and tumor size. A multivariate Cox regression model suggested that SCGB3A1 expression, pathological type, and ethnicity independently impact patient prognosis. Functional enrichment analysis indicated that SCGB3A1 was related to tumor progression, cell proliferation, and immune suppression. Furthermore, ssGSEA analysis revealed that SCGB3A1 expression is associated with immune cell infiltration and tumor-related immune genes. Experimental validation suggested that the overexpression of SCGB3A1 suppressed cell proliferation, migration, and invasion of LUAD.</p><p><strong>Conclusions: </strong>In summary, this study investigated the association between SCGB3A1 and the prognosis of early-stage lung adenocarcinoma. The findings revealed that SCGB3A1 is related to immune cell infiltration and tumor-related immune gene expression, which may provide insights into the role of SCGB3A1 in immunotherapy. The cytological experiments indicate that SCGB3A1 is a potential therapeutic target for LUAD.</p>","PeriodicalId":8915,"journal":{"name":"BMC Medical Genomics","volume":"18 1","pages":"119"},"PeriodicalIF":2.0000,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12281796/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medical Genomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12920-025-02192-7","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Many early-stage lung adenocarcinoma patients experience recurrence or metastasis after surgery, and the efficacy of targeted therapies remains suboptimal, significantly impacting the prognosis of these patients. Our study aims to investigate the impact of SCGB3A1 on the prognosis of lung adenocarcinoma patients and its role in immunity. We propose that SCGB3A1 may offer a novel treatment approach for lung adenocarcinoma patients who do not respond well to targeted therapies.

Methods: We obtained RNA sequencing data from 539 lung adenocarcinoma samples, 59 normal tissues, and 2 metastatic cancer tissues from The Cancer Genome Atlas database. Using Venn diagrams, we analyzed the expression of SCGB3A1 and other differentially expressed genes (DEGs) in different patient groups. Additionally, we performed another Venn diagram analysis to explore the association between SCGB3A1 and immune-related genes. We investigated the relationship between SCGB3A1 expression and patient clinical-pathological data and prognosis. Furthermore, through GO, KEGG, and GSEA enrichment analyses, we explored the functional roles of SCGB3A1 and its association with immune cell infiltration and immune checkpoint genes. The role of SCGB3A1 in LUAD was investigated by cytological experiments.

Results: The results indicated that SCGB3A1 is associated with both prognosis and immunity. In lung adenocarcinoma, SCGB3A1 may function as a tumor suppressor gene. The high-expression group of SCGB3A1 exhibited a better prognosis and more pronounced immune cell infiltration. Additionally, SCGB3A1 was associated with smoking status and tumor size. A multivariate Cox regression model suggested that SCGB3A1 expression, pathological type, and ethnicity independently impact patient prognosis. Functional enrichment analysis indicated that SCGB3A1 was related to tumor progression, cell proliferation, and immune suppression. Furthermore, ssGSEA analysis revealed that SCGB3A1 expression is associated with immune cell infiltration and tumor-related immune genes. Experimental validation suggested that the overexpression of SCGB3A1 suppressed cell proliferation, migration, and invasion of LUAD.

Conclusions: In summary, this study investigated the association between SCGB3A1 and the prognosis of early-stage lung adenocarcinoma. The findings revealed that SCGB3A1 is related to immune cell infiltration and tumor-related immune gene expression, which may provide insights into the role of SCGB3A1 in immunotherapy. The cytological experiments indicate that SCGB3A1 is a potential therapeutic target for LUAD.

SCGB3A1表达在I期肺腺癌中的预后意义及免疫调节作用。
背景:许多早期肺腺癌患者术后出现复发或转移,靶向治疗的效果仍不理想,严重影响患者的预后。我们的研究旨在探讨SCGB3A1对肺腺癌患者预后的影响及其在免疫中的作用。我们认为SCGB3A1可能为靶向治疗反应不佳的肺腺癌患者提供一种新的治疗方法。方法:从The cancer Genome Atlas数据库中获取539例肺腺癌样本、59例正常组织和2例转移性癌组织的RNA测序数据。利用维恩图,我们分析了SCGB3A1和其他差异表达基因(DEGs)在不同患者组中的表达。此外,我们进行了另一项维恩图分析,以探索SCGB3A1与免疫相关基因之间的关联。我们研究了SCGB3A1表达与患者临床病理资料和预后的关系。此外,通过GO、KEGG和GSEA富集分析,我们探索了SCGB3A1的功能作用及其与免疫细胞浸润和免疫检查点基因的关联。通过细胞学实验探讨SCGB3A1在LUAD中的作用。结果:SCGB3A1与预后和免疫均相关。在肺腺癌中,SCGB3A1可能作为肿瘤抑制基因发挥作用。SCGB3A1高表达组预后更好,免疫细胞浸润更明显。此外,SCGB3A1与吸烟状况和肿瘤大小有关。多变量Cox回归模型提示SCGB3A1表达、病理类型和种族独立影响患者预后。功能富集分析表明SCGB3A1与肿瘤进展、细胞增殖和免疫抑制有关。此外,ssGSEA分析显示SCGB3A1表达与免疫细胞浸润和肿瘤相关免疫基因有关。实验验证表明,过表达SCGB3A1可抑制LUAD细胞的增殖、迁移和侵袭。结论:综上所述,本研究探讨了SCGB3A1与早期肺腺癌预后的关系。研究结果表明,SCGB3A1与免疫细胞浸润和肿瘤相关免疫基因表达有关,这可能为SCGB3A1在免疫治疗中的作用提供新的见解。细胞学实验表明SCGB3A1是LUAD的潜在治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Medical Genomics
BMC Medical Genomics 医学-遗传学
CiteScore
3.90
自引率
0.00%
发文量
243
审稿时长
3.5 months
期刊介绍: BMC Medical Genomics is an open access journal publishing original peer-reviewed research articles in all aspects of functional genomics, genome structure, genome-scale population genetics, epigenomics, proteomics, systems analysis, and pharmacogenomics in relation to human health and disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信